Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02491775 · ClinicalTrials.gov registry record
Afatinib Genomic Landscape
A clinical trial, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- 6
- Enrollment target
NCT02491775: Clinical Trial study, sponsored by Washington University School of Medicine.
NCT02491775 is a clinical trial that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02491775 was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The investigators propose to conduct a pilot feasibility study of single agent afatinib in patients with previously untreated metastatic EGFR (epidermal growth factor receptor) mutant adenocarcinoma of the lung (NSCLC = non-small cell lung cancer) with the sole purpose of characterizing the genomic landscape before afatinib and at the time of disease progression.
Primary Outcome
* The investigators will compare tumor sequencing prior to afatinib treatment to the time of disease progression to see if the genetic sequencing changed between pre-treatment and progression. * The investigators plan to conduct exome and transcriptome sequencing of tumor before therapy with afatinib and at the time of relapse. In addition, exome sequencing of peripheral blood DNA will be done (for germline). Given the complexities of genomic analyses of paired samples in the face of limited dat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-06-11 |
| Est. Completion | 2018-02-28 |
Why NCT02491775 stopped before completion
NCT02491775 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02491775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02491775 about?
NCT02491775 is a clinical study titled "Afatinib Genomic Landscape". The investigators propose to conduct a pilot feasibility study of single agent afatinib in patients with previously untreated metastatic EGFR (epidermal growth factor receptor) mutant adenocarcinoma of the lung (NSCLC = non-small cell lung cancer) with the sole purpose of characterizing the genomic ...
What is the current status of trial NCT02491775?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2015-06-11. Estimated completion is 2018-02-28.
Who is sponsoring clinical trial NCT02491775?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI